Skip to main content
SpringerLink
Log in

LopiGLIK lowers LDL cholesterol at lower cost than Armolipid Plus

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. cardiovascular disease

Reference

  • Manfrin A, et al. A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK) lowering cardiovascular disease risk ClinicoEconomics and Outcomes Research : 8 Oct 2018. Available from: URL: https://doi.org/10.2147/CEOR.S172838

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

LopiGLIK lowers LDL cholesterol at lower cost than Armolipid Plus. PharmacoEcon Outcomes News 814, 13 (2018). https://doi.org/10.1007/s40274-018-5356-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5356-6

Search

Navigation